Display options
Cite
Sardari S, Azadmanesh K, Mahboudi F, et al. Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna J Med Biotechnol. 2013;5(2):78-86
Sardari, S., Azadmanesh, K., Mahboudi, F., Davood, A., Vahabpour, R., Zabihollahi, R., & Gomari, H. (2013). Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna journal of medical biotechnology, 5(2), 78-86.
Sardari, Soroush, et al. "Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay." Avicenna journal of medical biotechnology vol. 5,2 (2013): 78-86.
Sardari S, Azadmanesh K, Mahboudi F, Davood A, Vahabpour R, Zabihollahi R, Gomari H. Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna J Med Biotechnol. 2013 Apr;5(2):78-86. PMID: 23799176; PMCID: PMC3689560.
Copy Download .nbib Format: NLM
Share it on

Avicenna J Med Biotechnol. 2013 Apr;5(2):78-86.

Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay.

Avicenna journal of medical biotechnology

Soroush Sardari, Kayhan Azadmanesh, Fereidoun Mahboudi, Asghar Davood, Ruhollah Vahabpour, Rezvan Zabihollahi, Hosna Gomari

Affiliations

  1. Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

PMID: 23799176 PMCID: PMC3689560

Abstract

BACKGROUND: Gp41 of HIV (Human Immunodeficiency Virus) is a protein that mediates fusion between viral and cellular membranes. The agent, T-20, which has been approved for HIV inhibition, can restrain Gp41 function in the fusion process; nevertheless, it has disadvantages like instability, high cost of production and injection form to be delivered twice a day.

METHODS: Several molecules like NB-2 and NB-64 have been discovered that can inhibit HIV infection. These molecules were used as template compounds to design and develop more effective small molecules functioning as HIV-1 fusion inhibitors targeting Gp41. The process included in silico docking protocols using HEX and ArgusLab applications. A multisource database was created, after choosing the best molecules; they were tested in vitro for inhibitory activity by HIV-1 single-cycle model, transfected in HEK cells (293T).

RESULTS: Computational analysis and experimental data were combined to explore molecular properties and the most potent ones were found, with the best suitable criteria for interaction with Gp41. Several examples (DAA-6, DAA-9 and DAA-12) could inhibit infection in vitro as effective as NB-2, NB-64.

CONCLUSION: Since disadvantages of available fusion inhibitor (T-20), it seems necessary to find similar molecules to be approved and have small size providing suitable bioactivity profile. The molecules explored in this study can be good candidates for further investigations to be used as oral HIV fusion inhibitors in the future.

Keywords: Antagonists and inhibitors; Drug design; Flow cytometry; HIV fusion inhibitors

References

  1. J Biol Chem. 2012 Feb 24;287(9):6788-96 - PubMed
  2. Conf Proc IEEE Eng Med Biol Soc. 2005;2005:4755-8 - PubMed
  3. Biochem Biophys Res Commun. 2007 Mar 23;354(4):872-8 - PubMed
  4. J Med Chem. 1999 Aug 26;42(17):3203-9 - PubMed
  5. AIDS Res Hum Retroviruses. 2002 Sep 20;18(14):989-97 - PubMed
  6. J Biol Chem. 1993 Jul 25;268(21):15343-6 - PubMed
  7. Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13938-43 - PubMed
  8. Microbes Infect. 2006 Feb;8(2):520-32 - PubMed
  9. Curr Pharm Des. 2002;8(8):563-80 - PubMed
  10. Curr Pharm Des. 2007;13(2):143-62 - PubMed
  11. Molecules. 2010 Dec 30;16(1):221-50 - PubMed
  12. Acta Virol. 2011;55(1):15-22 - PubMed
  13. Antimicrob Agents Chemother. 2011 Feb;55(2):722-8 - PubMed
  14. Antimicrob Agents Chemother. 2004 Nov;48(11):4349-59 - PubMed
  15. Biochem Biophys Res Commun. 1996 Oct 23;227(3):724-9 - PubMed
  16. Bioinformatics. 2007 Jan 15;23(2):e104-9 - PubMed
  17. Bioorg Med Chem. 2008 Mar 15;16(6):3039-48 - PubMed
  18. Retrovirology. 2007 Aug 08;4:55 - PubMed
  19. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5036-41 - PubMed
  20. Antimicrob Agents Chemother. 2005 Sep;49(9):3926-9 - PubMed
  21. J Biol Chem. 2007 Aug 31;282(35):25631-9 - PubMed
  22. Arch Pharm (Weinheim). 2006 Jun;339(6):299-304 - PubMed
  23. Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11013-8 - PubMed
  24. Antimicrob Agents Chemother. 2009 Dec;53(12):4987-98 - PubMed

Publication Types